This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571)

Published on in Vol 9, No 7 (2020): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/16162, first published .
Alterations of Gut Microbiota and the Brain-Immune-Intestine Axis in Patients With Relapsing-Remitting Multiple Sclerosis After Treatment With Oral Cladribine: Protocol for a Prospective Observational Study

Alterations of Gut Microbiota and the Brain-Immune-Intestine Axis in Patients With Relapsing-Remitting Multiple Sclerosis After Treatment With Oral Cladribine: Protocol for a Prospective Observational Study

Alterations of Gut Microbiota and the Brain-Immune-Intestine Axis in Patients With Relapsing-Remitting Multiple Sclerosis After Treatment With Oral Cladribine: Protocol for a Prospective Observational Study

Authors of this article:

Jeske van Pamelen1 Author Orcid Image ;   Lynn van Olst2 Author Orcid Image ;   Andries E Budding3 Author Orcid Image ;   BIA Study Group4 ;   Helga E de Vries2, 5 Author Orcid Image ;   Leo H Visser1 Author Orcid Image
Article Authors Cited by (3) Tweetations (5) Metrics

Journals

  1. Uniyal A, Tiwari V, Rani M, Tiwari V. Immune-microbiome interplay and its implications in neurodegenerative disorders. Metabolic Brain Disease 2022;37(1):17 View
  2. Preiningerova J, Jiraskova Zakostelska Z, Srinivasan A, Ticha V, Kovarova I, Kleinova P, Tlaskalova-Hogenova H, Kubala Havrdova E. Multiple Sclerosis and Microbiome. Biomolecules 2022;12(3):433 View
  3. Del Negro I, Pez S, Versace S, Marziali A, Gigli G, Tereshko Y, Valente M. Impact of Disease-Modifying Therapies on Gut–Brain Axis in Multiple Sclerosis. Medicina 2023;60(1):6 View